Momenta chronicles
Momenta (MNTA) dropped 58% last week after the company and partner Sandoz received a not approvable letter from FDA for an ANDA for M-Enoxaparin. The stock has dropped more than 80% since its peak in September 2005, just after it submitted the ANDA. Selected events since the company's IPO are tracked below against MNTA's weekly stock price.
A. 6/22/04 - Momenta (MNTA) raises $40M in IPOB. 11/5/04 - In an earnings release, says it remains on track to file an ANDA for M-Enoxaparin by mid-2005C. 6/16/05 - Gains $6.36 (63%) to $16.50 after a U.S. court issues a ruling that, if finalized, would lift the 30-month stay on FDA approval of generic versions of Lovenox enoxaparin from sanofi-aventis(Euronext:SAN; SNY)D. 7/21/05 - Raises $130.4M in a follow-on...